BOSTON, SHANGHAI, and SUZHOU – January 13, 2026, SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, announced that the first patient has recently been dosed in a Phase 1 clinical trial of SGB-7342 at the first hospital of Jilin University in China. This randomized, double-blind, placebo controlled, single ascending dose Phase 1 clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SGB-7342 in overweight and obese patients.
SGB-7342 is an investigational GalNAc-conjugated siRNA medicine for the treatment of obesity targeting Inhibin Beta E (INHBE) messenger RNA (mRNA) in hepatocytes. It incorporates SanegeneBio’s proprietary GalNAc configuration and oligonucleotide chemistry, which has resulted in potentially best-in-class Phase 1 performance for several other recent investigational siRNA medicines. SGB-7342 is designed to silence the INHBE gene through an RNAi mechanism, thereby reducing circulating Activin E levels and inhibiting downstream signaling pathways involved in lipid metabolism and energy expenditure. In preclinical studies, SGB-7342 demonstrated robust INHBE silencing, loss of body weight and fat mass, preservation of lean mass, and a favorable safety and tolerability profile.
Dr. Yuyan Jin, Senior Vice President of Clinical and Nonclinical Development at SanegeneBio, stated:
“The first patient dosed with SGB-7342 marks a significant milestone in its development. Leveraging the RNAi mechanism, it has the potential to achieve selective fat loss while preserving lean muscle, offering a novel, differentiated treatment strategy for obesity. This achievement also represents a solid step forward in SanegeneBio’s strategic commitment to developing innovative therapies for obesity and metabolic diseases. We will advance the subsequent clinical development of SGB-7342, striving to bring this transformative therapy to patients with obesity worldwide.”
About SanegeneBio
SanegeneBio is a global, venture-backed, fully-integrated biotechnology company focused on developing RNAi-based therapeutics. Founded in 2021 and led by a team of RNAi veterans, the company has R&D operations in Boston, Shanghai and Suzhou. Their clear vision is that RNAi technology will power blockbuster medicines in diverse therapeutic areas, improving the quality and longevity of life for patients worldwide. This vision is being realized by advancing a fast-growing pipeline, which includes experimental medicines for autoimmune nephropathies, obesity, and cardiometabolic indications. SanegeneBio has initiated clinical trials for four experimental medicines to-date, and is committed to developing potential best-in-class and first-in-class therapeutics which leverage our industry-leading and differentiated LEAD™ tissue-selective RNAi delivery technology. For more information, please visit: www.sanegenebio.com and engage on LinkedIn.